A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Idiopathic pulmonary fibrosis (IPF) is when the lungs become scarred, and breathing becomes increasingly difficult. Damage to ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

Idiopathic Pulmonary Fibrosis (IPF) leads to thickening and stiffening of lung tissue, impairing gas exchange and causing ...

Ivaltinostat is under clinical development by CG Invites and currently in Phase I for Idiopathic Pulmonary Fibrosis.

A Wicklow woman whose father died earlier this year, after suffering with idiopathic pulmonary fibrosis, will mark Pulmonary ...

Top-line results were announced from a phase 3 trial evaluating nerandomilast an oral, investigational phosphodiesterase 4B inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF).

The emerging therapies for the treatment of idiopathic pulmonary fibrosis include a great deal of emerging drugs Tyvaso (treprostinil), BI 1015550, and others. The emerging therapies in the ...